By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PTC Therapeutics, Inc. 

100 Corporate Court

South Plainfield  New Jersey  07080-2449  U.S.A.
Phone: 908-222-7000 Fax: 908-222-7231


Drug Discovery

Company News
PTC Therapeutics (PTCT) Release: Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916 10/21/2016 6:49:03 AM
PTC Therapeutics (PTCT) Tanks After the FDA Denies DMD Drug Translarna Again 10/17/2016 6:25:09 AM
PTC Therapeutics (PTCT) Wants a Slice of Sarepta (SRPT)'s DMD Pie, Says Rejected Drug May Help Some Patients 10/7/2016 7:51:59 AM
PTC Therapeutics (PTCT) Release: New Research Validates Translarna's (Ataluren) Mechanism Of Action To Promote Readthrough Of Nonsense Mutations And Produce Full-Length Functional Protein 10/4/2016 9:34:17 AM
PTC Therapeutics (PTCT) Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/13/2016 6:56:04 AM
PTC Therapeutics (PTCT) Recognizes World Duchenne Awareness Day By Announcing Winners Of Global Duchenne Muscular Dystrophy Patient Group Awards And Expanding Disease State Awareness Website 9/7/2016 10:53:27 AM
PTC Therapeutics (PTCT) Reports Second Quarter 2016 Financial Results And Provides Corporate Update 8/5/2016 8:22:13 AM
PTC Therapeutics (PTCT) Provides Regulatory Update On Translarna (Ataluren) 7/25/2016 10:17:27 AM
PTC Therapeutics (PTCT) To Host Conference Call To Discuss Second Quarter Financial Results 7/21/2016 7:20:14 AM
In Conversation With Paul Martin, Lorraine Bracy And Natalie Bilci Of PTC Therapeutics (PTCT) Legal Department 6/22/2016 2:51:21 PM